欧洲区域乙型肝炎控制进展:2016-2019
In 2019, an estimated 14 million persons in the World Health Organization (WHO) European Region* (EUR) were chronically infected with hepatitis B virus (HBV), and approximately 43,000 of these persons died from complications of chronic HBV infection (1).…
要点
- 50/53国提供普遍HepB接种,23国提供出生剂量。
- 35/48国HepB3年覆盖率达90%以上,19/23国及时出生剂量达90%以上。
- 意大利和荷兰首批通过区域乙肝控制目标验证。
核心结论
- 欧洲区域在2016-2019年乙肝控制取得进展,但部分国家覆盖率未达2020目标。
研究设计与样本
- 基于WHO欧洲区域53个国家2016-2019年乙肝控制规划数据的进展报告。
主要发现
- 截至2019年12月,50国(94%)提供普遍HepB接种,其中23国(43%)为所有新生儿提供出生剂量。
- 48个普遍婴儿HepB接种国家中35个(73%)在2017-2019年每年HepB3覆盖率达90%以上。
- 23个普遍出生剂量国家中19个(83%)在2017-2019年每年及时HepB-BD覆盖率达90%以上。
- 30个选择性出生剂量国家中17个(57%)产前乙肝筛查覆盖率达90%以上。
关键数值与推荐
- 2020年目标:HepB3覆盖率达90%以上。
- 2020年目标:预防HBV母婴传播干预覆盖率达90%以上。
- 2020年目标:疫苗适龄人群HBsAg患病率不超过0.5%。
临床怎么用
- 提高HepB和母婴传播预防干预覆盖率以加速乙肝控制。
- 通过代表性血清学调查或低流行国家产前筛查记录HBsAg血清流行率达标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2019, an estimated 14 million persons in the World Health Organization (WHO) European Region* (EUR) were chronically infected with hepatitis B virus (HBV), and approximately 43,000 of these persons died from complications of chronic HBV infection (1). In 2016, the WHO Regional Office for Europe set hepatitis B control program targets for 2020, including 1) ≥90% coverage with 3 doses of hepatitis B vaccine (HepB3), 2) ≥90% coverage with interventions to prevent mother-to-child transmission (MTCT) of HBV,† and 3) ≤0.5% prevalence of HBV surface antigen (HBsAg)§ in age groups eligible for vaccination with hepatitis B vaccine (HepB) (2-4). This report describes the progress made toward hepatitis B control in EUR during 2016-2019. By December 2019, 50 (94%) of 53 countries in EUR provided routine vaccination with HepB to all infants or children aged 1-12 years (universal HepB), including 23 (43%) countries that offered hepatitis B birth dose (HepB-BD) to all newborns. In addition, 35 (73%) of the 48 countries with universal infant HepB vaccination reached ≥90% HepB3 coverage annually during 2017-2019, and 19 (83%) of the 23 countries with universal birth dose administration achieved ≥90% timely HepB-BD coverage¶ annually during that period. Antenatal hepatitis B screening coverage was ≥90% in 17 (57%) of 30 countries that selectively provided HepB-BD to infants born to mothers with positive HBsAg test results. In January 2020, Italy and the Netherlands became the first counties in EUR to be validated to have achieved the regional hepatitis B control targets. Countries can accelerate progress toward hepatitis B control by improving coverage with HepB and interventions to prevent MTCT and documenting achievement of the HBsAg seroprevalence target through representative serosurveys or, in low-endemicity countries, antenatal screening.
引用
- Khetsuriani N, Mosina L, Van Damme P, et al. Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34324482. doi:10.15585/mmwr.mm7030a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。